Share This

Related Topics News -

     
 Title only   |   Print    Next page > 
     
百濟神州替雷利珠單抗獲EC批准用於治療非小細胞肺癌

2024-04-24T  
美生物法案擬限制與中資合作 據報歐美多家藥廠正物色替代外包供應商

2024-04-11T  
《大行》美銀證券降百濟神州目標價至99.21元 評級「中性」

2024-04-10T  
高瓴轄下資產總值去年萎縮三分一 旗下基金據報面臨美投資者贖回

2024-04-08T  
《全日總結》恆指跌363點 長實集團及東方海外挫逾一成

2024-03-22T  
《半日總結》恆指跌512點 科指跌逾4% 長實集團挫近12%

2024-03-22T  
《大行報告》美銀證券升百濟神州目標價至108.27元 評級「中性」

2024-03-18T  
《大行報告》里昂微升百濟神州目標價至138.5元 PD-1在美國獲批符預期

2024-03-18T  
百濟神州替雷利珠單抗獲美國批准治療食管鱗狀細胞癌

2024-03-15T  
《大行報告》匯豐研究升百濟神州目標價至171元 BTK銷售持續突破市場預期

2024-03-05T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.